Pemazyre (Pemigatinib) Patent Expiration, LOE Window & CMS Spending

Pemazyre (Pemigatinib) by Incyte: FDA Orange Book core substance LOE 2040-10-03, 0 AB generics, $35.1M 2024 CMS Part D & Medicaid spend, and 3 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorIncyte
FDA Application & PathwayN213736 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2040-10-03
Last Listed Patent or Exclusivity Date2040-10-03
Orange Book Patents (*PED Extensions)5 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$35.1M
2024 Medicare Part D Spend$29.5M
2024 Medicaid Spend$5.5M
Reported Wholesale Price Change (CA SB 17)3 WAC filings (max 17.0% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Incyte across sibling Meru public-data platforms.